Lyndsey Hanson - Concepedia

Author

Lyndsey Hanson

AstraZeneca (United Kingdom)ORCID

Also Known As

L Hanson, L. Hanson, Lyndsey Hanson, Lyndsey L. Hanson

130

Publications

784

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)AstraZeneca (Singapore)Ionis Pharmaceuticals (United States)

About

Lyndsey Hanson is an author at AstraZeneca (United Kingdom) specializing in tumor biology, medicine, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	74
2	Natural Sciences	1	1	52
3	Biochemistry	1	1	52
4	Cell Biology	1	1	22
5	Chemical Biology	1	1	52

Lyndsey Hanson

Publications

746

Citations

H-Index

Page 1

	Year	Citations
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson, Science Translational Medicine	2017	175
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel Urs J. Hancox, Sabina Cosulich, Lyndsey Hanson, Molecular Cancer Therapeutics	2014	99
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS<sup>G12C</sup> Jason G. Kettle, Sharan K. Bagal, Sue Bickerton, Journal of Medicinal Chemistry	2020	80
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC) Richard A. Ward, Mark J. Anderton, Paul A. Bethel, Journal of Medicinal Chemistry	2019	75
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors Barry R. Davies, Nin Guan, Armelle Logié, Molecular Cancer Therapeutics	2015	70
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS<sup>G12C</sup> Jason G. Kettle, Sharan K. Bagal, Sue Bickerton, Journal of Medicinal Chemistry	2022	56
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point Richard A. Ward, Paul A. Bethel, Calum Cook, Journal of Medicinal Chemistry Structure-guided DiscoverySelective InhibitorsChemical BiologyPharmaceutical ChemistryTumor Biology	2017	52
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i> -Dependent Breast Cancers Kevin Hudson, Urs J. Hancox, Cath Trigwell, Molecular Cancer Therapeutics	2016	42
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i> -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib Vikki Flemington, Emma Jane Davies, David M. Robinson, Molecular Cancer Therapeutics	2020	26
The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers Barbara J. Brandhuber, Jennifer Haas, Brian B. Tuch, European Journal of Cancer MedicineRet-dependent CancersPathologyImmune Checkpoint InhibitorTumor Suppressor	2016	22

Page 1